Content about Nephropathy

April 22, 2011

An investigational antifibrotic and anti-inflammatory drug could help treat a common complication of diabetes.

NEW YORK — An investigational antifibrotic and anti-inflammatory drug could help treat a common complication of diabetes.

Researchers at the University of California-San Diego School of Medicine, the National Institutes of Health and the Mayo Clinic found that pirfenidone potentially could treat diabetic nephropathy, a leading cause of end-stage kidney disease.

October 14, 2010

The Food and Drug Administration has given orphan drug designation to a treatment for a...

STOCKHOLM The Food and Drug Administration has given orphan drug designation to a treatment for a rare kidney disease under mid-stage clinical development by privately owned Swedish drug maker PharmaLink, the company said.

 

The FDA granted the designation to Nefecon (PL-56), a treatment for IgA nephropathy, also known as Berger’s disease, a disorder that leads to end-stage kidney disease. The FDA gives orphan drug designation to incentivize development of treatments for rare and serious disorders.